1. |
Goldberg RM, Moertel CG, Wieand HS, et al. A phase Ⅲ evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic [J]. Cancer, 1995; 76(6)∶ 961.
|
2. |
Tomassetti P, Migliori M, Gullo L. Slowrelease lanreotide treatment in endocrine gastrointestinal tumors [J]. Am J Gastroenterol, 1998; 93(9)∶1468.
|
3. |
Eriksson B, Renstrup J, Imam H, et al. Highdose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects [J]. Ann Oncol, 1997; 8(10)∶1041.
|
4. |
Madeira I, Ruszniewski P. Digestive system carcinoid tumors: treatment [J]. Rev Med Interne, 1999; 20(5)∶421.
|
5. |
鄭永唐,賁昆龍. 測定細胞存活和增殖的MTT方法的建立 [J]. 免疫學雜志, 1992; 8(4)∶266.
|
6. |
Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [J]. Gut, 1996; 38(3)∶430.
|
7. |
Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors [J]. Digestion, 1999; 60(Suppl 2)∶9.
|
8. |
鄂征主編. 組織培養和分子細胞學技術 [M]. 第1版. 北京: 北京出版社, 1995∶203~205.
|
9. |
Di Leo A, Bajetta E, Ferrari L, et al. A dosefinding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma [J]. Cancer, 1996; 78(1)∶35.
|
10. |
Janson ET, Stridsberg M, Gobl A, et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies [J]. Cancer Res, 1998; 58(11)∶2375.
|
11. |
Qin Y, Ertl T, Groot K, et al. Somatostatin analog RC160 inhibits growth of CFPAC1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate [J]. Int J Cancer, 1995; 60(5)∶694.
|
12. |
Reisine T. Somatostatin receptors [J]. Am J Physiol, 1995; 269(6 Pt 1)∶G813.
|
13. |
吳蘇冬, 劉長利, 王慧川, 等. 參臼膠囊誘導肝癌SMMC7721細胞凋亡 [J]. 世界華人消化雜志, 2003; 11(7)∶908.
|